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INTRODUCTION
Postmenopausal bleeding (PMB) is defined 
as any vaginal bleeding occurring at least 
12 months after the last menstrual period.1 
It represents one of the most common rea-
sons for referral to the gynaecological ser-
vices, and the incidence is estimated to be 
around 10%.2 In 2004, it accounts for 2.5% 
of all gynaecological hospital admissions 
in Hong Kong,3 and it does not include 
many consultations that take place at the 
outpatient setting. In the United Kingdom, 
it accounts for about 5% of referrals to the 
gynaecology outpatient services.4
CAUSES OF PMB
Postmenopausal bleeding is alarming for 
both patients and clinicians because the 
classic teaching has labelled PMB as ‘en-
dometrial cancer until proven otherwise’. 
Depending on age and risk factors, 1–14% 
of women presenting with PMB will have 
underlying endometrial carcinoma.5 How-
ever, PMB in the majority of women is due 
to benign causes (Table 1), and the most 
common cause is atrophy of the vaginal 
mucosa or endometrium secondary to the 
lack of oestrogen production.6 It is there-
fore mandatory to evaluate any women 
with PMB promptly in order to exclude 
Table 1. Causes of postmenopausal 
bleeding
Condition
Women with 
the condition (%)
Atrophic 
vaginitis
59
Endometrial 
polyp
12
Endometrial 
hyperplasia
10
Endometrial 
carcinoma
10
Hormonal 
effect
7
Cervical 
carcinoma
2
Other < 1
Table 2. Risk factors for endometrial 
cancer
Risk factor Risk ratio
Overweight (age, 
50–59 years)
9–23 kg 3.0
> 23 kg 10.0
Nulliparity 2.0
Late menopause 2.4
Tamoxifen use 2.2
Diabetes mellitus 2.7
Unopposed 
oestrogen therapy
6.0
underlying malignancy, as early stage 
endometrial cancer is amenable to cura-
tive treatment. The National Institute for 
Clinical Excellence guidelines advise that 
when women, who are not on hormone 
replacement therapy (HRT), present with 
PMB, they should be urgently referred for 
specialist assessment and be seen within 
2 weeks of referral.7
MANAGEMENT OF PMB
History
A detailed medical and drug history may 
help the clinician differentiate the dif-
ferent causes of abnormal bleeding, and 
it should aim to identify the risk factors 
for endometrial carcinoma. Women taking 
the selective oestrogen receptor modula-
tor tamoxifen for breast cancer have two 
to three times higher risk of developing 
endometrial carcinoma than those of an 
age-matched population.8 Particular atten-
tion should also be paid to the use of HRT. 
Transient unscheduled bleeding is not un-
common during the first 6 months of con-
tinuous combined HRT and can be followed 
up, but PMB in unopposed oestrogen users 
with an intact uterus should prompt urgent 
investigation. Table 2 shows the risk fac-
tors for endometrial carcinoma and the 
respective relative risks when compared 
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with those without the risk factor.9
Examination
General examination including body mass 
index is an essential part of examination, 
as obesity is an independent variable as-
sociated with a significantly increased 
risk of endometrial cancer.10 Speculum 
examination, which allows visual inspec-
tion of the genital tract, helps to assess 
the degree of atrophic changes and to rule 
out tumours of the cervix, vagina or vulva, 
or cervical polyps. However, the finding of 
atrophic vaginitis or a polyp should not be 
accepted as the explanation for the bleed-
ing without further assessment of the en-
dometrial cavity. Cervical smear should 
also be taken. 
 
Investigation
The aim of investigating a woman present-
ing with PMB is to identify endometrial 
pathology, most notably to exclude endo-
metrial carcinoma. The principle of man-
agement is to achieve an accurate diagno-
sis with the least invasive investigation, 
if possible.
There is a range of diagnostic tests 
generally performed for women present-
ing with PMB. Specifically for the as-
sessment of the endometrium, there are 
essentially four methods: sonographic 
measurement of endometrial thickness, 
endometrial sampling, hysteroscopy under 
various modes of anaesthesia, and saline 
sonohysterography. These four tests have 
been independently shown to be useful in 
identifying endometrial pathologies with 
different degree of accuracy. However, 
for the use of these tests in the exclusion 
of endometrial carcinoma, there are still 
unresolved concerns regarding the appro-
priate initial method of evaluation and the 
combination or sequence in which these 
methods should be employed.1,5,11–13
Measurement of Endometrial 
Thickness
Transvaginal sonography (TVS) is a rela-
tively non-invasive investigation that is 
widely used in the evaluation of the endo-
metrium. Although histological diagnosis 
is not available, sonographic imaging is an 
extremely helpful test in assessing women 
with PMB because endometrial cancer is 
nearly always associated with thickening 
and heterogeneity of the endometrial lin-
ing.6,14 The endometrial thickness should 
be measured from a longitudinal scan 
through the thickest area of the endome-
trium and from the outermost border of the 
antero-posterior endometrium (Figure 1).
There are different endometrial 
thickness thresholds that have been used 
for recommending further investigations; 
understandably, the lower the cut-off level 
used, the fewer the number of cases of 
endometrial carcinoma that will be missed 
but at the cost of needing further inves-
tigations in a greater number of women 
without cancer. The use of the traditional 
cut-off value of 5 mm, with the sensitiv-
ity for detecting endometrial carcinoma 
of 96% and the specificity of 61%, was 
based on the meta-analysis of 35 prospec-
tive studies performed in 1998.15 Using 
this cut-off value, the probability of endo-
metrial cancer was reduced to 1% for a 
negative test. Subsequently, a meta-anal-
ysis and a consensus conference regarding 
the ability of TVS to detect endometrial 
pathology in women with PMB concluded 
that the negative predictive value of a thin 
endometrium of ≤ 4 mm was very high,12,16 
and the chance of having endometrial can-
cer is 1 in 917 in this group of patients.17 
The American College of Obstetricians and 
Gynecologists recommends that when TVS 
is performed for patients with PMB and an 
endometrial thickness of ≤ 4 mm is found, 
Figure 1. Measurement of endometrial thickness.
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endometrial sampling is not required.5 A 
more recent meta-analysis by Timmermans 
et al found a higher diagnostic accuracy 
for TVS with a cut-off value of ≤ 3 mm, 
in which the sensitivity was 98% and the 
specificity was 35%, giving a likelihood 
ratio for a negative test result of 0.06.18 
The Scottish Intercollegiate Guidelines 
Network suggests that a cut-off threshold 
of 3 mm or less should be used.1 On the 
other hand, cancer becomes increasingly 
more frequent as the endometrial thick-
ness approaches 15 mm, which is highly 
suggestive of endometrial carcinoma 
(Figure 2).16
Conditions like previous pelvic sur-
gery, coexisting leiomyoma, marked obe-
sity, and adenomyosis may preclude an 
accurate assessment of the endometrial 
thickness. In such cases, alternative as-
sessment like saline sonohysterography 
or endometrial sampling should be con-
sidered.
Saline Sonohysterography
Saline sonohysterography, an imaging 
technique in which normal saline is in-
stilled into the uterine cavity, allows bet-
ter detection of the endometrial polyp 
(Figure 3) and submucosal fibroid.19 In 
patients whose endometrial lining is not 
adequately visualized, it will allow an 
excellent depiction of the endometrial 
thickness. It will distinguish focal (Figure 
4) from global lesions when TVS shows a 
thick endometrial echo. It can therefore 
act as an adjunct to TVS to clarify abnor-
mal endometrial findings.20
One systematic review described 
the evaluation of the diagnostic accu-
racy of sonohysterography in pre- and 
postmenopausal women with abnormal 
uterine bleeding.21 The review showed 
that sonohysterography gave a sensitivity 
of 95% and a specificity of 88%, but the 
calculations for endometrial cancer were 
Figure 3. Sonohysterogram showing an endometrial polyp.
Figure 2. Thickened endometrium.
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not mentioned. In addition, Cheung et al 
suggested that the sonohysterographic 
appearance of endometrial carcinoma was 
variable and could even be normal. There-
fore, sonohysterography should not be 
used as an initial investigation for women 
with PMB.22
Endometrial Sampling
A definitive diagnosis of endometrial 
carcinoma is made by histology. The de-
velopment of equipment and techniques 
for office-based endometrial biopsy has 
generally replaced the need for dilatation 
and curettage performed in the hospital. 
The current standard suction piston biopsy 
equipment known as the Pipelle is a plastic 
disposable catheter with its own internal 
piston to generate suction. Pipelle sam-
pling has been shown to be more sensitive 
for the detection of endometrial cancer 
and atypical hyperplasia when compared 
with all other sampling devices.23 Howev-
er, it was found to miss 8–33% of cancer 
cases, especially for focal tumours.24–26 In 
a meta-analysis which assessed the ac-
curacy of outpatient endometrial biopsy in 
the diagnosis of endometrial cancer found 
that the post-test probability of endome-
trial cancer after a positive test was 82% 
(95% confidence interval, 60–93%), and 
after a negative test it was 0.9% (95% 
confidence interval, 0.4–2.4%).27 In this 
analysis, 15% of specimens were inad-
equate and one case of cancer was sub-
sequently found among these patients; 
therefore, inadequate sampling is always 
one of the drawbacks of this technique. 
Farrell et al demonstrated that for women 
whose Pipelle result was insufficient, 20% 
had uterine pathology after further inves-
tigations, and 3% had malignancies.28 In 
a small proportion of patients, outpatient 
endometrial sampling is not technically 
possible owing to stenotic cervical os. 
 
Hysteroscopy
Hysteroscopy provides direct visualization 
of the endometrial cavity, thereby allow-
ing targeted biopsy during the procedure. 
However, it is more costly and invasive 
than most other modalities of endome-
trial assessment. A quantitative review 
showed a sensitivity and specificity of 
86.4% and 99.2%, respectively, and its 
accuracy was related to diagnosing rather 
than excluding cancer.29
Sequence of Investigations
The US guidelines recommend either TVS 
or outpatient endometrial sampling as 
the first step in evaluating women with 
PMB.5,12 The Canadian guideline recom-
mends office endometrial biopsy as the 
initial choice of procedure owing to its 
convenience, accuracy, availability, safe-
ty, and low cost.13 In other guidelines, 
the first step is TVS, based on the high 
sensitivity and non-invasive character of 
There is still  
controversy about  
the cut-off value 
for endometrial 
thickness
Figure 4. Sonohysterogram showing focal thickening of the endometrium.
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the procedure.1,11 The ideal setting will 
be ‘one-stop’ specialist clinics where in-
vestigations including TVS, endometrial 
sampling and hysteroscopy are available 
to complement clinical evaluation at the 
same time. Depending on the resources 
available, initial endometrial sampling 
may be appropriate if obtaining TVS would 
delay assessment. If TVS is readily avail-
able, endometrial sampling is only needed 
if the endometrial thickness is above the 
cut-off value as suggested by the Euro-
pean guidelines.1,11 However, the excep-
tion applies to women taking tamoxifen, 
as hysteroscopy with biopsy is preferably 
the first line of investigation in view of 
the high false-positives with ultrasonog-
raphy.1,8 Saline sonohysterography can be 
added to distinguish between diffuse and 
focal pathology, and hysteroscopy will be 
advised if focal lesion is found. The exact 
sequence of investigation will depend 
upon clinical judgment, local resources, 
local expertise, and patient preference. 
The available evidence evaluated the dif-
ferent investigations independently, with-
out any consideration of combinations of 
tests or previous test results. Clark et al 
constructed a decision model and evalu-
ated 12 different strategies for the initial 
investigation of PMB.30 It was concluded 
that a strategy with TVS as the initial test 
with a cut-off of 4 mm followed by endo-
metrial sampling was most cost-effective 
while strategies involving initial evalua-
tion with test combinations or hysteros-
copy alone were not.
RECOMMENDATIONS/
SUMMARY
•  PMB should always be investigated, 
as 10% of patients will have endome-
trial carcinoma.
About 10% of women presenting with postmenopausal bleeding will have endometrial carcinoma.
Hysteroscopy  
should not be the  
first-line investigation  
for PMB except  
for women taking 
tamoxifen
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• The most common cause of PMB is 
atrophic vaginitis or endometritis.
•  Speculum examination should always 
be performed to rule out local lesions.
• Either endometrial biopsy or TVS can be 
used as initial investigation depending 
on the availability of resources.
• There is still controversy about the cut-
off value for endometrial thickness. The 
traditional ≤ 4 mm cut-off has a high 
negative predictive value for malig-
nancy, and endometrial biopsy is not 
necessary unless in cases of recurrent 
bleeding.
• Insufficient sample from endometrial 
biopsy should always lead to further 
investigations.
• Hysteroscopy should not be the first-
line investigation for PMB except for 
women taking tamoxifen.
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Answer True or False to the questions below.
1. The incidence of postmenopausal bleeding is estimated to be around 20%.
2. The most common cause of postmenopausal bleeding is endometrial carcinoma.
3. Women with postmenopausal bleeding should be urgently referred for specialist assessment and be 
seen within 4 weeks of referral.
4. Using an endometrial thickness cut-off value of 5 mm, the probability of endometrial carcinoma is 1% 
for a negative test.
5. An ultrasound finding of thickened endometrium in women with postmenopausal bleeding should 
prompt further investigation with endometrial sampling for histology. 
6. Saline sonohysterography should be used as an initial investigation for women with postmenopausal 
bleeding because it can distinguish focal from global lesions.
7. With an inadequate endometrial sampling, we can comfortably exclude underlying endometrial 
carcinoma.
8. Tamoxifen use is a risk factor for endometrial carcinoma, and hysteroscopy should be the first-line 
investigation for this group of women.
9. Either transvaginal ultrasound or endometrial biopsy can be used as initial investigation for 
postmenopausal bleeding.
10. Women with endometrial thickness of 3 mm but with recurrent bleeding do not require further 
investigation.
 True False
CME Questions
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